ClinicalTrials.Veeva

Menu

Blueberry Intake and Infant Gut Health

University of Colorado Denver (CU Denver) logo

University of Colorado Denver (CU Denver)

Status

Completed

Conditions

Infant Development

Treatments

Other: Placebo Powder
Other: Blueberry Powder

Study type

Interventional

Funder types

Other

Identifiers

NCT05006989
20-1659

Details and patient eligibility

About

The objective of this project is to investigate the effects of blueberries on gut microbiota, inflammation and innate immunity in breastfed infants during early complementary feeding (~5 to 12 months of age).

Full description

Some details are intentionally left to out to preserve the scientific integrity of the study, and they will be included in the record after the study is completed.

Enrollment

75 patients

Sex

All

Ages

4 to 5 months old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Generally healthy
  • Full term (gestational age ≥ 37 weeks)
  • No prior exposure of solid foods
  • Exclusively breastfed (< 2 weeks of cumulative formula exposure)
  • Willing to consume blueberry/placebo powder

Exclusion criteria

  • Having health conditions that would affect normal growth
  • Pre-term
  • Consumed formula for more than two weeks
  • Not willing to consume the blueberry/placebo powders

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

75 participants in 2 patient groups, including a placebo group

Intervention Group
Experimental group
Description:
Participants will be provided pre-made whole blueberry freeze-dried powder to be consumed.
Treatment:
Other: Blueberry Powder
Placebo Group
Placebo Comparator group
Description:
Placebo powder with matching color and texture.
Treatment:
Other: Placebo Powder

Trial contacts and locations

1

Loading...

Central trial contact

Minghua Tang, PhD; Lillian Berman, MS

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems